Sun Pharmaceutical Industries and the Technion–Israel institute of technology have entered into an exclusive worldwide research and licence agreement for the development of novel anti-cancer drugs.
The joint project would be based on new findings by Nobel Prize laureate Professor Aaron Ciechanover, Gila Maor and Professor Ofer Binah, a note from Sun Pharma said.
The research development comes weeks after Sun sealed its $4-billion deal to merge troubled drugmaker Ranbaxy.
The institute’s pre-clinical research was funded this far by Dr Alfred Mann. The Technion and Sun Pharma alliance will advance this project through pre-clinical development process, said Ciechanover and Binah, adding that they had explored several alternatives in the past.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.